From Wikipedia, the free encyclopedia
Jump to: navigation, search
SCH-48461 structure.png
IUPAC name
148260-92-8 YesY
ChemSpider 117230 N
Jmol-3D images Image
PubChem 132832
Molar mass 401.49748
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N verify (what isYesY/N?)
Infobox references

SCH-48461 is a cholesterol absorption inhibitor.[1][2]

The prototypical 2-azetidinone CAI (cholesterol absorption inhibitor) SCH-48461 was a predecessor to the drug Ezetimibe.

During the early phases of an ACAT inhibitor discovery program at Schering-Plough, conformationally restricted analogs based on the 2-azetidinone backbone were targeted by Burnett and co-workers.[3] Early in the biological evaluation, it became apparent that even though the in vitro ACAT inhibitory activity of these analogs was modest (e.g., IC50 values of 2–50 mM), they exhibited significant activity in a cholesterol-fed hamster model (CFH). The discovery of the prototypical 2-azetidinone CAI, SCH-48461 (ACAT IC50 ~26 mM, ED50 of CE reduction in hamsters ~2.2 mpk) and the details of the first-generation SAR have been described in detail.[4]

SCH-48461 reduced LDL-C by –13% at a daily dose of 25 mg.


  1. ^ Salisbury BG, Davis HR, Burrier RE et al. (May 1995). "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461". Atherosclerosis 115 (1): 45–63. doi:10.1016/0021-9150(94)05499-9. PMID 7669087. 
  2. ^ Dujovne CA, Bays H, Davidson MH et al. (January 2001). "Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study". J Clin Pharmacol 41 (1): 70–8. doi:10.1177/00912700122009854. PMID 11144997. 
  3. ^ Burnett, Duane A. (1994). "2-Azetidinones as Inhibitors of Cholesterol Absorption". Journal of Medicinal Chemistry 37 (12): 1733–1736. doi:10.1021/jm00038a001.  edit
  4. ^ Clader, John W. (1996). "2-Azetidinone Cholesterol Absorption Inhibitors:  Structure−Activity Relationships on the Heterocyclic Nucleus". Journal of Medicinal Chemistry 39 (19): 3684–3693. doi:10.1021/jm960405n.  edit